We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Now, scientists in Korea have discovered that the Parkinson’s disease drug procyclidine can alleviate physical symptoms of ...

AI predicts Parkinson’s disease using medical and prescription data, enhancing early diagnosis and research into new ...

A new study from the University of East Anglia has found that long-term use of certain antidepressants may increase the risk of dementia, even if taken up to 20 years before a diagnosis. The study ...

A woman who is at least the fourth generation of her family to suffer a "cruel" brain disorder, which leaves people trapped ...

Sixteen tin foil wraps were found inside the Kinder egg tube and, after analysis, it was confirmed they contained 1.34g of cocaine, with an estimated value of between £160 and £240. Downloads of the ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...